Table 1 Study population characteristics
All | Receiving statin therapy | |
|---|---|---|
n = 924 | n = 730 | |
Clinical | ||
Age (years) | 65 [58, 70] | 65 [59, 70] |
Male sex, n (%) | 597 (65) | 486 (67) |
Diabetes duration (years) | 11 [6, 17] | 11 [6, 17] |
Body mass index (kg/m2) | 29 [26, 33] | 30 [27, 33] |
Systolic blood pressure (mmHg) | 136 (17) | 135 (16) |
Diastolic blood pressure (mmHg) | 80 (11) | 80 (10) |
Known coronary heart disease n (%) | 162 (18) | 140 (19) |
Lipids | ||
Total cholesterol (mmol/l) | 4.1 [3.5, 4.8] | 3.9 [3.4, 4.5] |
Low density cholesterol (mmol/l) | 2.0 [1.6, 2.6] | 1.8 [1.5, 2.3] |
High density cholesterol (mmol/l) | 1.2 [1.0, 1.4] | 1.2 [1.0, 1.4] |
Cholesterol remnants (mmol/l) | 0.8 [0.5, 1.1] | 0.7 [0.5, 1.0] |
Triglyceride (mmol/l) | 1.7 [1.2, 2.4] | 1.7 [1.2, 2.4] |
Other laboratory values | ||
Albuminuria (%) | 212 (23.3) | 165 (22) |
Microalbuminuria (%) | 149 (16) | 116 (16) |
Macroalbuminuria (%) | 63 (7) | 49 (7) |
Creatinine (μmol/l) | 78 [65, 96] | 78 [66, 96] |
Haemoglobin A1c (%) | 55 [48, 66] | 54 [48, 65] |
Haemoglobin A1c (mmol/mol) | 7.2 [6.5, 8.2] | 7.1 [6.5, 8.1] |
Medication | ||
Statins, n (%) | 730 (79) | – |
Metformin, n (%) | 670 (73) | 552 (76) |
DPP4 inhibitors, n (%) | 88 (10) | 71 (10) |
Sulfonylurea, n (%) | 142 (15) | 107 (15) |
Glucagon-like peptide-1 receptor agonists, n (%) | 226 (25) | 189 (26) |
Insulin, n (%) | 428 (46) | 334 (46) |
Beta blockers, n (%) | 221 (24) | 186 (26) |
Angiotensin-converting enzyme inhibitors, n (%) | 354 (38) | 297 (41) |
Angiotensin II receptor blockers, n (%) | 359 (40) | 298 (41) |
Calcium antagonists, n (%) | 294 (32) | 250 (34) |
Diuretics, n (%) | 452 (49) | 376 (52) |
Antiplatelets, n (%) | 607 (66) | 508 (70) |